| Concentration: | 1 mg / ml, determined by the Lowry method |
| Source: | Bovine Serum Albumin was purchased from Boehringer Mannheim and was modified by carbamylation to form CBL modified BSA. |
| Buffer: | In 10 mM PBS, 0.15 M NaCl 0.5 mM EDTA, 0.01 % NaN3, pH 7.4. |
| Storage: | -20°C for short and long-term storage. Aliquot to avoid repeated freezing and thawing. |
*The products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.
Importance
Carbamylation is a spontaneous nonenzymatic modification of proteins and amino acids by urea-derived isocyanate, which is generally present in human serum and is increased in uremic patients (Kraus and Kraus, 2001).
Proteins carbamylated at lysine or the terminal protein amino acids may play an important role in Chronic renal failure subjects in the development of atherosclerosis and cardiovascular diseases (Raine et al., 1991; Culleton et al., 1999).
Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999; 56: 2214–9.
Kraus LM, Kraus AP Jr. Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl 2001; 78: S102–7.
Raine AE, MacMahon SH, Selwood NH, Wing AJ, Brunner FP. Mortality from myocardial infarction in patients on renal replacement therapy. Nephrol Dial Transplant 1991; 6: 902.
academy biomed[A05]绵羊抗人类载脂蛋白AII多克隆抗体12A-S1a学院生物医学公司$ 155.00$ 155.00目录号数量1寄主物种： 羊浓度： 1毫克/毫升（OD 1.35 / 280 nm）抗原： 人类载脂蛋白AII纯化： 亲和纯化缓冲： 75 mM磷酸钠，75 mM NaCl，0.5 mM EDTA，0.02％NaN3，pH 7.2特异性 与人载脂蛋白AII特异性结合。免疫印迹和ELISA的稀释范围：1,000至80,000。用： 该抗体可用于检测血浆和脂蛋白中的载脂蛋白AII，免疫测定，免疫印迹，酶结合或生物素化。存储： -20°C长期保存，4°C短期保存。等分试样，以避免反复冻结和解冻。 *这些产品仅用于研究或制造用途，不能用于人体治疗或诊断应用。 重要性Apo AII占HDL的25％。它在人血浆中以77条氨基酸残基的2条相同链的二聚体形式存在，并通过二硫键连接。据报道，单链的分子量为8.7kDa（Brewer等，1972）。对小鼠的研究报道，apoAII可能具有促动脉粥样硬化作用（Warden等，1993）。然而，一项大型的欧洲前瞻性研究中的病例对照研究表明，血浆Apo AII浓度与冠心病事件密切相关（Birjmohun等，2007）。Birjmohun，RS，GM Dallinga-Thie，JA Kuivenhoven，ESg Stroes，JD Otvos，NJ Wareham，R.Luben，JJp Kastelein，K.-T. Khaw和SM Boekholdt。“载脂蛋白A-II与未来冠状动脉疾病的风险成反比。” 循环116（2007）：2029-035。Brewer，HB，SE Lux，R.Ronan和KM John。“人ApoLp-Gln-II（apoA-II），一种从高密度脂蛋白复合物中分离的载脂蛋白的氨基酸序列。” 美国国家科学院院刊69.5（1972）：1304-308。Warden，C.，C.Hedrick，J.Qiao，L.Castellani和A.Lusis。“过表达载脂蛋白A-II的转基因小鼠中的动脉粥样硬化。” 科学261（1993）：469-72。
